Cite
Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.
MLA
Rao, Yong, et al. “Bouchardatine Analogue Alleviates Non-Alcoholic Hepatic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in High-Fat Fed Mice by Inhibiting ATP Synthase Activity.” British Journal of Pharmacology, vol. 176, no. 16, Aug. 2019, pp. 2877–93. EBSCOhost, https://doi.org/10.1111/bph.14713.
APA
Rao, Y., Lu, Y., Li, C., Song, Q., Xu, Y., Xu, Z., Hu, Y., Yu, H., Gao, L., Gu, L., Ye, J., Huang, Z., Lu, Y.-T., Song, Q.-Q., Xu, Y.-H., Hu, Y.-T., Gu, L.-Q., Ye, J.-M., & Huang, Z.-S. (2019). Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity. British Journal of Pharmacology, 176(16), 2877–2893. https://doi.org/10.1111/bph.14713
Chicago
Rao, Yong, Yu‐Ting Lu, Chan Li, Qin‐Qin Song, Yao‐Hao Xu, Zhao Xu, Yu‐Tao Hu, et al. 2019. “Bouchardatine Analogue Alleviates Non-Alcoholic Hepatic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in High-Fat Fed Mice by Inhibiting ATP Synthase Activity.” British Journal of Pharmacology 176 (16): 2877–93. doi:10.1111/bph.14713.